Journal of Clinical Endocrinology & Metabolism, Vol 57, 1314-1316, Copyright © 1983 by Endocrine Society

ARTICLES

Salmon and human calcitonin-like peptides coexist in the human thyroid and brain

JA Fischer, PH Tobler, H Henke and FA Tschopp

A salmon calcitonin-like material indistinguishable from synthetic salmon calcitonin-(1-32) on high performance liquid chromatography (HPLC) has been recognized in thyroid extracts of normal subjects and of patients with medullary carcinoma. The same peptide was detected in extracts of the periventricular mesencephalic region which included the periventricular dorsal thalamus, the subthalamus and the hypothalamus. Human calcitonin-(1-32)- and carboxyl-terminal adjacent peptide (CCAP)- like components were also found. The content of immunoreactive salmon calcitonin of the periventricular mesencephalic region (n = 6) and of normal thyroid glands (n = 6) was comparable (mean +/- SE, 0.34 +/- 0.17 ngeq/g wet tissue and 0.39 +/- 0.22 ngeq/g, respectively); and the levels were slightly, but not significantly higher in medullary thyroid carcinoma extracts (1.95 +/- 0.69 ngeq/g) (P less than 0.1). Immunoreactive human calcitonin and CCAP occurred in roughly equimolar concentrations. They were lowest in the periventricular mesencephalic region (0.26 +/- 0.09 ngeq/g and 0.46 +/- 0.10 ngeq/g, respectively), followed by normal thyroid glands (146 +/- 26 ngeq/g and 94 +/- 19 ngeq/g, respectively), and they were highest in medullary thyroid carcinoma tissue (680 +/- 372 mu geq/g and 144 +/- 125 mu geq/g, respectively).

This article has been cited by other articles:

				S. Thomas, S. Chigurupati, M. Anbalagan, and G. Shah Calcitonin Increases Tumorigenicity of Prostate Cancer Cells: Evidence for the Role of Protein Kinase A and Urokinase-Type Plasminogen Receptor Mol. Endocrinol., August 1, 2006; 20(8): 1894 - 1911. [Abstract] [Full Text] [PDF]

				H. Sawada, H. Yamaguchi, T. Shimbara, K. Toshinai, M. S. Mondal, Y. Date, N. Murakami, T. Katafuchi, N. Minamino, H. Nunoi, et al. Central Effects of Calcitonin Receptor-Stimulating Peptide-1 on Energy Homeostasis in Rats Endocrinology, April 1, 2006; 147(4): 2043 - 2050. [Abstract] [Full Text] [PDF]

				T. Katafuchi, K. Kikumoto, K. Hamano, K. Kangawa, H. Matsuo, and N. Minamino Calcitonin Receptor-stimulating Peptide, a New Member of the Calcitonin Gene-related Peptide Family. ITS ISOLATION FROM PORCINE BRAIN, STRUCTURE, TISSUE DISTRIBUTION, AND BIOLOGICAL ACTIVITY J. Biol. Chem., March 28, 2003; 278(14): 12046 - 12054. [Abstract] [Full Text] [PDF]

				C. N. Papandreou, D. D. Daliani, P. F. Thall, S.-M. Tu, X. Wang, A. Reyes, P. Troncoso, and C. J. Logothetis Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate J. Clin. Oncol., July 15, 2002; 20(14): 3072 - 3080. [Abstract] [Full Text] [PDF]

				G. V. Shah, J. Chien, Y. P. Sun, S. Puri, and R. Ravindra Calcitonin Inhibits Anterior Pituitary Cell Proliferation in the Adult Female Rats Endocrinology, September 1, 1999; 140(9): 4281 - 4291. [Abstract] [Full Text]

				J. M. Hilton, K. I. Mitchelhill, G. Pozvek, M. Dowton, M. Quiza, and P. M. Sexton Purification of Calcitonin-Like Peptides from Rat Brain and Pituitary Endocrinology, March 1, 1998; 139(3): 982 - 992. [Abstract] [Full Text] [PDF]